Discrepancies between consensus documents, clinical guidelines and legislation in the treatment of type 2 diabetes

被引：9

作者：

Martinez-Castelao, Alberto ^{[1
]}

Gorriz, Jose L. ^{[2
]}

Sola, Eva ^{[3
]}

Morillas, Carlos ^{[3
]}

Jover, Ana ^{[3
]}

Coronel, Francisco ^{[4
]}

Navarro-Gonzalez, Juan ^{[5
]}

de Alvaro, Fernando ^{[6
]}

机构：

[1] Hosp Univ Bellvitge, Serv Nefrol, IDIBELL, Barcelona 08907, Spain

[2] Hosp Univ Dr Peset, Serv Nefrol, Valencia, Spain

[3] Hosp Univ Dr Peset, Serv Endocrinol, Valencia, Spain

[4] Hosp Clin San Carlos, Serv Nefrol, Madrid, Spain

[5] Hosp Univ Nuestra Senora Candelaria, Serv Nefrol, Santa Cruz De Tenerife, Spain

[6] Hosp Univ Infanta Sofia, Serv Nefrol, Madrid, Spain

来源：

NEFROLOGIA | 2012年 / 32卷 / 04期

关键词：

IMPROVES GLYCEMIC CONTROL; RENAL IMPAIRMENT; HUMAN ULTRALENTE; PHARMACOKINETICS; MANAGEMENT; INSULIN; HYPERGLYCEMIA; VILDAGLIPTIN; SITAGLIPTIN; METFORMIN;

D O I：

10.3265/Nefrologia.pre2012.Jun.11576

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：419 / 426

页数：8

共 25 条

[1]

[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]

[2]

[Anonymous], TYP 2 DIAB MAN TYP 2

[3]

[Anonymous], ADV PERIT DIAL

[4] Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency [J].

Chan, J. C. N. ;

Scott, R. ;

Ferreira, J. C. Arjona ;

Sheng, D. ;

Gonzalez, E. ;

Davies, M. J. ;

Stein, P. P. ;

Kaufman, K. D. ;

Amatruda, J. M. ;

Williams-Herman, D. .

DIABETES OBESITY & METABOLISM, 2008, 10 (07) :545-555

[5]

Charpentier G, 2000, DIABETES METAB, V26, P73

[6]

Coronel Diaz F, 1984, Med Clin (Barc), V82, P881

[7] Metformin therapy in patients with chronic kidney disease [J].

Duong, J. K. ;

Roberts, D. M. ;

Furlong, T. J. ;

Kumar, S. S. ;

Greenfield, J. R. ;

Kirkpatrick, C. M. ;

Graham, G. G. ;

Williams, K. M. ;

Day, R. O. .

DIABETES OBESITY & METABOLISM, 2012, 14 (10) :963-965

[8]

Fine A, 2000, PERITON DIALYSIS INT, V20, P652

[9] USE OF HUMAN ULTRALENTE AS THE BASAL INSULIN COMPONENT IN TREATMENT OF PATIENTS WITH IDDM [J].

FREEMAN, SL ;

OBRIEN, PC ;

RIZZA, RA .

DIABETES RESEARCH AND CLINICAL PRACTICE, 1991, 12 (03) :187-192

[10] Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin [J].

Graefe-Mody, U. ;

Friedrich, C. ;

Port, A. ;

Ring, A. ;

Retlich, S. ;

Heise, T. ;

Halabi, A. ;

Woerle, H. -J. .

DIABETES OBESITY & METABOLISM, 2011, 13 (10) :939-946

← 1 2 3 →